Immunowake

Executive Summary

Immunowake is a preclinical-stage Chinese biotechnology company dedicated to developing innovative immunotherapies and vaccines for infectious diseases and oncology. Founded in 2016 and headquartered in Suzhou, the company leverages advanced immunological research to create next-generation vaccine candidates and immune-modulating therapeutics aimed at significant unmet medical needs. With a lean team of 1–50 employees, Immunowake operates in the highly competitive immuno-oncology and vaccine landscapes, focusing on both preventive and therapeutic applications. The company's platform-based approach seeks to harness the immune system to address chronic infections and cancers, potentially offering differentiated mechanisms of action. As a private, preclinical entity, Immunowake's progress is likely dependent on securing funding, advancing lead candidates into IND-enabling studies, and generating compelling preclinical data. The company's stage implies high risk but also potential for significant upside if key milestones are achieved. Given the lack of publicly disclosed pipeline details or recent funding rounds, Immunowake remains an early-stage venture with limited visibility. Near-term catalysts could include the announcement of a new financing round, strategic partnerships with larger biopharma firms, or the release of preclinical efficacy data for its lead vaccine or immunotherapy candidates. Success in these areas would be critical for transitioning into clinical development and attracting further investment.

Upcoming Catalysts (preview)

• Q4 2026Completion of Series A or B Financing Round60% success
• Q2 2027Release of Preclinical Efficacy Data for Lead Immunotherapy Candidate40% success
• 2027Announcement of a Strategic Partnership or Licensing Deal with a Major Pharma30% success